|
Synonyms: BMS-936557 | MDX-1100
Compound class:
Antibody
Comment: Eldelumab (BMS-936557 and formerly MDX-1100) is a a fully human monoclonal antibody targeting the chemokine CXCL10 (a.k.a. interferon-γ-inducible protein-10 or IP-10) [1]. It is being investigated for its anti-inflammatory action in autoimmune conditions.
BLAST peptide sequence analysis reveals exact matches with heavy and light chain variable regions claimed in patent US8258266, and identify eldelumab as clone 6A5 [1]. |
| Bioactivity Comments |
| Eldelumab does not bind other identified CXCR3 ligands CXCL9 (a.k.a. MIG) and CXCL11 (a.k.a. ITAC) [1]. |
| Selectivity at ligand targets | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
